APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial BOSTON, April 11, 2022 — APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a […]
Privacy Policy
Privacy Policy Last updated: May 04, 2022 This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Website and tells You about Your privacy rights and how the law protects You. We use Your Personal data to provide and improve the Website. By using […]
Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery
Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.
APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development With Biogen Inc.
APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantification of abnormal tau protein accumulation in the brain.
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for 18F-APN-1607 Tau PET Imaging Tracer for Dementia
APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease
APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer’s Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.
APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan
APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.
APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation
APRINOIA’s lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.
US FDA Approved APRINOIA Conduct Clinical Trial
APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.
HMWoTau ELISA
APRI.HMWoTauELISA Service About our HMWoTau ELISA Our highly sensitive novel ELISA detects HMWoTau species in a disease-specific manner. Our ELISA (APRI.HMWoTauELISA) employs APNmAb005 mouse monoclonal antibody that recognizes HMWoTau (about 30 nm diameter), labelled by Thioflavin (Fig. 1). APRI.HMWoTauELISA detected Alzheimer’s disease (AD)-derived HMWoTau species, in a dilution dependent manner (Fig.2A) and at Braak Stage […]